On December 4, 2025 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported that the company has been awarded a $10.8 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the continued clinical investigation of IMGS-001 in patients with solid tumors. IMGS-001, the company’s lead program, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is being studied in a phase 1a/b dose-escalation and dose-expansion trial (NCT06014502). The focus of this grant, the company’s second from CPRIT, will be to support the phase 1b dose-expansion portion of the trial across multiple solid tumor cohorts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The phase 1b expansion focuses on demonstrating safety and initial clinical benefit in multiple solid tumor cohorts characterized by a high degree of immune exclusion where CD8 T cells—the immune system’s soldiers—are present but locked out of the tumor. IMGS-001 has been specifically engineered to drive clinical benefit in this patient population through its multifunctional mechanism of cell killing and PD-1 signal blockade.

"CPRIT has played a pivotal role in enabling ImmunoGenesis’ growth. The first award of $15.5 million in 2020 allowed us to establish our Texas headquarters, complete essential nonclinical studies, obtain IND clearance, and begin the phase 1a trial of IMGS-001," said James Barlow, CEO of ImmunoGenesis. "With this second award, we can build on the early signs of clinical activity and accelerate evaluation of IMGS-001 for immune-excluded tumor cohorts with high unmet need."

The award underscores CPRIT’s mission to support novel research. IMGS-001 is based on discoveries made by the laboratory of Dr. Michael A. Curran at The University of Texas MD Anderson Cancer Center and the Oncology Research for Biologics & Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division. Dr. Curran founded ImmunoGenesis and the technology was licensed to the company in 2019.

"ImmunoGenesis was previously awarded a CPRIT grant in 2020 to fund early development of IMGS-001," said CPRIT CEO Kristen Doyle. "The company successfully hit the goals and objectives of the original grant. Given this initial grant and the CPRIT funding provided to Dr. Curran in the early development work, CPRIT’s expert review panel that recommended funding saw this as an exciting opportunity for CPRIT to continue to support a novel molecule that has shown initial promise in early clinical testing."

ImmunoGenesis is headquartered in Houston, and the CPRIT award will enable the company to continue strengthening its leadership team and corporate infrastructure within the biotech community. Mr. Barlow added, "We are thrilled to contribute to, and grow within, the dynamic biotech ecosystem in Houston and across Texas."

(Press release, ImmunoGenesis, DEC 4, 2025, View Source;research-institute-of-texas-cprit-to-accelerate-the-clinical-development-of-imgs-001-for-patients-with-immune-excluded-tumors-with-high-unmet-need-302632467.html [SID1234661135])

On December 4, 2025 Immorta Bio reported the publication of a landmark preclinical study in the Journal of Translational Medicine demonstrating that its novel immunotherapy, SenoVax, dramatically reduces multiple types of solid tumors in murine models. Earlier this year, Immorta Bio filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper, titled "Reduction of Solid Tumors by Senescent Cell Immunization," was authored in collaboration with leading researchers from the University of Miami, Cedars-Sinai, UC San Diego, the Institute for Human Optimization, George Washington University, and Translational and Advanced Biosciences.

Full text: View Source In well-characterized mouse models of aggressive cancers, SenoVax, a personalized autologous immunotherapy that trains the immune system to attack senescent cells, achieved significant tumor shrinkage across lung, glioblastoma (brain), pancreatic, and breast cancers.

Senescent cells, which accumulate with age and chronic stress, are increasingly implicated in creating an immunosuppressive, pro-tumor microenvironment. By targeting antigens uniquely expressed on these cells, SenoVax appears to reprogram the tumor microenvironment, turning immunologically "cold" tumors "hot" by boosting CD8⁺ T-cell infiltration and reducing immune-suppressive cell populations. Key findings:

Statistically significant tumor growth inhibition and prolonged survival in both orthotopic and syngeneic models

Robust CD8⁺ T-cell infiltration and depletion of immunosuppressive cells in treated tumors

Strong activity as monotherapy and in combination with other treatments
"These data provide compelling proof-of-concept that immunizing against senescent cells represents an entirely new therapeutic modality in oncology," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio and lead author of the study. "We have already filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer and are completing the GMP manufacturing required to begin the study."

Dr. Gilberto Lopes, Chief of Thoracic Medical Oncology at the Sylvester Comprehensive Cancer Center (University of Miami) and study co-author, commented: "Many deadly solid tumors remain resistant to current immunotherapies because they are immunologically ‘cold.’ Converting the tumor microenvironment into a more inflamed, T-cell-friendly state by eliminating senescent cells could dramatically broaden the reach of checkpoint inhibitors and other immune therapies."

Dr. Boris Reznik, Chairman and CEO of Immorta Bio and senior author, added: "This publication lays a strong translational foundation for bringing senescent-cell-targeted therapies into the clinic, not only for cancer, but potentially for the many age-related diseases driven by pathologic cellular senescence."

The publication describes preclinical experiments in validated murine models demonstrating that immunization with SenoVax—a personalized, autologous immunotherapy designed to elicit immune responses against senescent cells—was associated with reduced tumor burden in lung, brain, pancreatic, and breast cancer settings. Senescent cells are increasingly recognized as contributors to tumor progression, immune evasion, and chronic inflammation. The work builds on prior evidence that removing senescent cells can modify the tumor microenvironment and may enhance antitumor immunity.

"These findings support further investigation of senescent-cell–targeted immunotherapy in oncology," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio and first author of the study. "Immorta Bio has submitted IND #30745 to the FDA for a planned first-in-human study in lung cancer and is completing the required GMP manufacturing run to enable initiation."

"Therapeutic resistance remains a major challenge, particularly in tumors with limited immune infiltration," said Dr. Gilberto Lopes, Chief of Medical Oncology at the University of Miami and second author of the publication. "These preclinical results raise the possibility that targeting senescent cells could improve immune responsiveness and complement existing treatment approaches."

Dr. Boris Reznik, Chairman and CEO of Immorta Bio and senior author, added: "This study provides foundational evidence for clinical development of senescent-cell–directed therapies in oncology, with potential future application to other aging-related biological processes."

(Press release, Immorta Bio, DEC 4, 2025, View Source [SID1234661134])

On December 4, 2025 Innovent Biologics (HKEX: 01801) reported that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent’s next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, "IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward."

Under the agreement:

Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.
Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China.
Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).

Detailed information about the collaboration can be found at the official website of Innovent Biologics.

(Press release, Innovent Biologics, DEC 4, 2025, View Source [SID1234661133])

On December 4, 2025 TransThera Sciences Inc. ("TransThera") reported the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and futibatinib. However, resistance to these agents commonly arises due to secondary FGFR2 mutations.

In a multicenter, open-label Phase 2 trial (NCT04919642), patients with FGFR2 fusion-positive CCA who had either primary resistance or developed acquired resistance to prior FGFR inhibitor (FGFRi) therapy were enrolled, along with patients harboring other FGFR alterations or FGFR wiled-type tumors. Tinengotinib demonstrated clinical activity in patients with FGFR2 fusion-positive CCA with acquired FGFRi resistance, as well as in those with other FGFR-altered subtypes.

Dr. Milind Javle of The University of Texas MD Anderson Cancer Center, corresponding author of the publication, stated: "We currently have two FDA-approved therapies targeting FGFR2 fusions in CCA. But resistance remains a major clinical challenge. As such, next generation FGFR inhibitors capable of overcoming resistance are urgently needed. Tinengotinib, as a multi-kinase FGFR inhibitor, is designed to inhibit both FGFR and compensatory pathways contributing to resistance. In this phase 2 study, tinengotinib demonstrated durable responses and meaningful clinical benefit. These promising results provide a strong rationale to proceed with a Phase 3 registration study".

Dr. Jean Fan, Chief Medical Officer of TransThera, also commented: "We are very pleased that the clinical trial results have gained peer recognition and were published in such a prestigious journal. This study provides important insights into treatment strategies for patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory or relapsed CCA, including the comparison of tinengotinib versus physician’s choice. We are committed to advancing global enrollment and delivering new treatment options for patients with metastatic cholangiocarcinoma."

Disclaimer: This article serves as a press release by TransThera to disclose the company’s latest developments. It is not intended as a product promotion advertisement and does not constitute the company’s or investment advice.

About Tinengotinib

Tinengotinib is an internally discovered, registrational clinical stage, multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs and VEGFRs, mitotic kinases Aurora A/B and Janus kinases (JAK). Ongoing clinical trials in the US and China have revealed the potential of tinengotinib to be efficacious in various solid tumors. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA, the Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) in China, the Orphan Drug Designation (ODD) for the treatment of biliary tract cancer by the European Medicines Agency (EMA). It was also approved for inclusion in the Priority Review and Approval Procedure by the NMPA for the treatment of CCA.

(Press release, TransThera Biosciences, DEC 4, 2025, View Source [SID1234661132])

On December 4, 2025 AstraZeneca reported its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, 6-9 December 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year’s ASH (Free ASH Whitepaper) congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations.

Key presentations include:

Phase I trial of surovatamig: Updated results at three-year follow up from the ongoing first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed/refractory (R/R) follicular lymphoma (FL) (Oral Abstract #1005).
DURGA-1 Phase Ib/II study: Initial data for AZD0120 in patients with R/R multiple myeloma (MM). AZD0120 is an investigational BCMAxCD19 chimeric antigen receptor T-cell (CAR T) therapy (Oral Abstract #269).
ECHO Phase III trial: Results after 50 months of follow up evaluating Calquence (acalabrutinib) plus bendamustine and rituximab in the first-line treatment of mantle cell lymphoma (MCL) (Oral Abstract #885).
ALXN1210-TMA-314 Phase III trial: Additional results from the open-label trial evaluating Ultomiris (ravulizumab) in paediatric patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) (Oral Abstract #1052).
Anas Younes, Senior Vice President, Haematology R&D and Chief Medical Officer, AstraZeneca, said: "We are advancing a broad pipeline of investigational therapies with the potential to redefine patient care across multiple types of blood cancer. At ASH (Free ASH Whitepaper), we are sharing meaningful progress with early efficacy and safety data for AZD0120, our first cell therapy, in multiple myeloma, and for surovatamig, a novel T-cell engager, in B-cell malignancies."

Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: "At ASH (Free ASH Whitepaper), we look forward to demonstrating how pioneering science can drive meaningful advances for people living with rare haematologic conditions. New data on Ultomiris, including Phase III results in paediatric patients with HSCT-TMA, will show clinically meaningful overall survival and improved outcomes, highlighting our ongoing pursuit to realise the full potential of our medicines and their impact on treating rare conditions."

Additional highlights include:

SYRUS Phase I/II trial: Updated safety and efficacy data for surovatamig in adolescent and adult patients with R/R B-cell acute lymphoblastic leukaemia (Abstract #3345)
Phase I trial of surovatamig: Initial efficacy and safety data for surovatamig in R/R diffuse large B-cell lymphoma (Abstract #5514)
AZD0120: Follow-up data from two investigator-initiated trials (IIT) in China evaluating AZD0120 as a first-line therapy in high-risk, newly diagnosed MM (Oral Abstract #258).
TrAVeRse Phase II trial: Preliminary results evaluating Calquence plus venetoclax and rituximab in treatment-naïve MCL patients (Oral Abstract #884).
AMPLIFY Phase III trial: Exploratory analyses supporting the safety and efficacy profile of Calquence in first-line chronic lymphocytic leukaemia, with new subgroup data evaluating the impact of prognostic mutations on clinical outcomes (Poster Abstract #3898).
ALPHA Phase III trial: Sub-analysis of results evaluating Voydeya (danicopan) as add-on to Ultomiris or Soliris (eculizumab) in adults with paroxysmal nocturnal haemoglobinuria (PNH) and clinically significant extravascular haemolysis, including in patients with advanced age (Oral Abstract #949).
Ultomiris: Real-world evidence highlighting the impact of Ultomiris in certain patient subgroups across approved indications, including in pregnant patients (Poster Abstracts #6238 and #4458).
Key presentations during the 67th ASH (Free ASH Whitepaper) Annual Meeting and Exposition

Lead Author

Abstract Title

Presentation Details (ET)

Awan, F et al.

Budget Impact of Fixed Duration Acalabrutinib in Combination with Venetoclax in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

Abstract #2627

Poster Abstract Session

Session 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I

6 December 2025
5:30 PM – 7:30 PM

Cheah, C et al.

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the Phase 3 ECHO trial

Abstract #3578

Poster Abstract Session

Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

7 December 2025
6:00 PM – 8:00 PM

Ghia, P et al.

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Abstract #3898

Poster Abstract Session

Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

7 December 2025
6:00 PM – 8:00 PM

Hawkes, E et al.

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAVeRse study

Abstract #884

Oral Abstract Session

Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL

8 December 2025
3:00 PM – 03:15 PM

Hou, J-Z et al.

Real-world incidence of treatment-emergent (TE) cardiovascular (CV) events among chronic lymphocytic (CLL)/small lymphocytic lymphoma (SLL) patients receiving acalabrutinib (acala) or zanubrutinib (zanu) monotherapy

Abstract #4506

Poster Abstract Session

Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

7 December 2025
6:00 PM – 8:00 PM

Seymour, JF et al.

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the Phase 3 AMPLIFY trial

Abstract #2118

Poster Abstract Session

Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

6 December 2025
5:30 PM – 7:30 PM

Wang, ML et al.

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Abstract #885

Oral Abstract Session

Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL

8 December 2025
3:15 PM – 3:30 PM

Ultomiris (ravulizumab)

Schoettler, M et al.

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

Abstract #1052

Oral Abstract Session

Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects

8 December 2025
4:45 PM – 05:00 PM

Chaudhury, S et al.

Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab

Abstract #4266

Poster Abstract Session

Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II

7 December 2025
6:00 PM – 8:00 PM

Sherrard, H et al.

Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis

Abstract #4458

Poster Abstract Session

Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II

7 December 2025
6:00 PM – 8:00 PM

Gandhi, S et al.

Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: Insights from the international PNH registry

Abstract #6238

Poster Abstract Session

Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

8 December 2025
6:00 PM – 8:00 PM

Fasenra (benralizumab)

Klion et al.

Efficacy and safety of benralizumab in patients with hypereosinophilic syndrome: Results from the Phase 3 natron study

Abstract #79

Oral Abstract Session

Session 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
06 December, 2025
9:30 AM – 9:45 AM

Klion et al.

Patient perspectives on the burden of hypereosinophilic syndrome: Results from the Phase 3 natron interview sub-study

Abstract #4465

Poster Presentation

Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
07 December, 2025
6:00 PM – 8:00 PM

Voydeya (danicopan)

Kulasekararaj, A et al.

Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: A sub-analysis of the phase 3 ALPHA trial

Abstract #949

Oral Abstract Session

Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care

8 December 2025
2:45 PM – 03:00 PM

Surovatamig

Aldoss, I et al.

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the Phase 1/2 SYRUS study

Abstract #3345

Poster Abstract Session

Session 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

7 December 2025
6:00 PM – 8:00 PM

Cheah, C et al.

SOUNDTRACK-B: A Phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell Non-Hodgkin lymphoma

Abstract #3747 (TiP)

Poster Abstract Session

Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II

7 December 2025
6:00 PM – 8:00 PM

Hou, JZ et al.

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) follicular lymphoma (FL)

Abstract #1005

Oral Abstract Session

Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Follicular Lymphoma

8 December 2025
5:00 PM – 5:15 PM

Kim, TM et al.

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-negative complete responses in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Abstract #5514

Poster Abstract Session

Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III

8 December 2025
6:00 PM – 8:00 PM

AZD0120

Du, J et al.

A dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma

Abstract #258

Oral Abstract Session

Session 655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma

6 December 2025
2:15 PM – 2:30 PM

Richard, S et al.

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary results from the DURGA-1 Phase 1b/2 study

Abstract #269

Oral Abstract Session

Session 704. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma

6 December 2025
3:00 PM – 3:15 PM

Feng, J et al.

One-year follow-up of CD19/BCMA dual-targeting FasTCAR-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Abstract #2384

Poster Abstract Session

Session 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I

6 December 2025
5:30 PM – 7:30 PM

Lentzsch, S et al.

ALACRITY: A Phase 1b/2 Study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in Participants with Relapsed or Refractory Light Chain Amyloidosis (AL)

Abstract #8236

ePublication

3 November 2025

AZD4512

Han, H et al.

AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies

Abstract #3296

Poster Abstract Session

Session 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II

7 December 2025
6:00 PM – 8:00 PM

(Press release, AstraZeneca, DEC 4, 2025, View Source [SID1234661131])